BCAL Diagnostics Issues New Shares to Service Provider Under Cleansing Notice

The latest update is out from BCAL Diagnostics Limited ( (AU:BDX) ).

BCAL Diagnostics has issued 615,651 new shares to a service provider at a deemed price of $0.09475 per share under ASX Listing Rule 7.1, expanding its share capital without undertaking a public disclosure document. The company confirmed it is up to date with its financial reporting and continuous disclosure obligations and stated there is no excluded information that would need to be disclosed to the market under the Corporations Act.

The cleansing notice under section 708A(5)(e) allows the newly issued shares to be traded on an unrestricted basis, supporting the company’s ability to compensate service providers with equity. This move underscores BCAL Diagnostics’ ongoing use of its placement capacity while signalling to investors that regulatory compliance and transparency requirements have been satisfied as at the date of the notice.

The most recent analyst rating on (AU:BDX) stock is a Hold with a A$0.11 price target. To see the full list of analyst forecasts on BCAL Diagnostics Limited stock, see the AU:BDX Stock Forecast page.

More about BCAL Diagnostics Limited

BCAL Diagnostics Limited operates in the medical diagnostics sector, focusing on developing and commercialising diagnostic technologies, including applications for healthcare markets. The company is listed on the ASX and is subject to Australian corporate reporting and continuous disclosure obligations, reflecting its position in the regulated public capital markets.

Average Trading Volume: 276,515

Technical Sentiment Signal: Strong Buy

Current Market Cap: A$44.17M

Learn more about BDX stock on TipRanks’ Stock Analysis page.